Research progress of Levonorgestrel intrauterine contraceptive system for gynecological diseases
YI Ting-yan1 LI Jian-xia2 LUO Xue-mei1▲
1.Department of Clinical Medicine,Jishou University Medical College,Hu′nan Province,Jishou 416000,China；
2.The First Department of Gynecology,Xiangxi Tujia and Miao Autonomous Prefecture People′s Hospital,Hu′nan Province,Jishou 416000,China
Abstract：Levonorgestrel intrauterine contraceptive system (LNG-IUS),as a new type of intrauterine hormone contraceptive device imported from abroad,is a safe,effective and acceptable contraceptive method.LNG-IUS is released into uterine cavity at a dose of 20 μg Levonorgestrel (LNG) per day,which has comprehensive effects of thickening cervical mucus,preventing sperm from moving in uterine cavity and fallopian tube,inhibiting endometrial proliferation,etc.Like oral contraceptives,it has therapeutic effects other than contraception.LNG-IUS can effectively treat various gynecological diseases,including menorrhagia,hysteromyoma,endometriosis and adenomyosis with dysmenorrhea and endometrial hyperplasia.It can be used as an alternative to hysterectomy for women with bleeding problems,and can protect the endometrium in estrogen replacement therapy,and even has a certain alleviation effect on the early stage of endometrial cancer.This article aims to discuss the research progress of LNG-IUS in the treatment of gynecological diseases.
易婷艳；李建霞；罗雪梅. 左炔诺孕酮宫内节育系统治疗妇科疾病的研究进展[J]. 中国当代医药, 2020, 27(5): 16-18转33.
YI Ting-yan； LI Jian-xia；LUO Xue-mei. Research progress of Levonorgestrel intrauterine contraceptive system for gynecological diseases. 中国当代医药, 2020, 27(5): 16-18转33.
Davies J，Kadir RA.Heavy menstrual bleeding：An update on management[J].Thromb Res，2017，151（Supp-S1）：S70-S77.
[1]
Costescu DJ.Levonorgestrel-releasing intrauterine systems for long-acting contraception：current perspectives，safety，and patient counseling[J].Int J Womens Health，2016，13（8）：589-598.
[2]
Committee on Practice Bulletins-Gynecology，Long-Acting Reversible Contraception Work Group.Practice bulletin No.186：long-acting reversible contraception：implants and intrauterine devices[J].Obstet Gynecol，2017，130（5）：251-269.
[3]
Giraldo PC，Souza TC，Henrique GL，et al.Reactional changes in short-term levonorgestrel-releasing intrauterine system（lng-ius）use[J].Rev Assoc Med Bras（1992），2019，65（6）：857-863.
[4]
Koh SC，Singh K.The effect of levonorgestrel－releasing intrauterine system use on menstrual blood loss and the hemostatic，fibrinolytic inhibitor systems in women with menorrhagia[J].J Thromb Haemost，2007，5（1）：133-138.
[5]
Heikinheimo O，Gemzell-Danielsson K.Emerging indications for the levonorgestrel-releasing intrauterine system（LNG-IUS）[J].Acta Obstet Gynecol Scand，2012，91（1）：3-9.
[6]
Kim ML，Seong SJ.Clinical applications of levonorgestrel-releasing intrauterine system to gynecologic diseases[J].Obstet Gynecol Sci，2013，56（2）：67-75.
[7]
Varma R，Sinha D，Gupta JK.Non-contraceptive uses of levonorgestrel-releasing hormone system（LNG-IUS）-a systematic enquiry and overview[J].Eur J Obstet Gynecol Reprod Biol，2006，125（1）：9-28.
[8]
Yang X，Li X，Wang Y，et al.Practices and knowledge of female gynecologists regarding contraceptive use：a real-world Chinese survey[J].Reprod Health.2018，15（1）：115.
[9]
Rezk M，Elshamy E，Shaheen AE，et al.Effects of a levonorgestrel intrauterine system versus a copper intrauterine device on menstrual changes and uterine artery Doppler[J].Int J Gynaecol Obstet，2019，145（1）：18-22.
[10]
Yang H，Xu X，Jiang X，et al.Treatment of menorrhagia due to aplastic anemia by hysteroscopic resection of endometrial functional layer and levonorgestrel-releasing intra-uterine system：three case reports[J].Medicine（Baltimore），2019，98（17）：e151-e156.
[12]
Wrona W，Stepniak A，Czuczwar P.The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids[J].Prz Menopauzalny，2017，16（4）：129-132.
[13]
Kaunitz AM.Progestin-releasing intrauterine systems and leiomyoma[J].Contraception，2007，75（6 Suppl）：130-133.
[14]
WHO.Medical eligibility criteria for contraceptive use：5thedition 2015[M].Geneva：World Health Organization，2015.
[15]
Sohn GS，Cho S，Kim YM，et al.Current medical treatment of uterine fibroids[J].Obstet Gynecol Sci，2018，61（2）：192-201.
[16]
Dunselman GA，Vermeulen N，Becker C，et al.ESHRE guideline：management of women with endometriosis[J].Hum Report，2014，29（3）：400-412.
Kim MK，Seong SJ，Kim JW，et al.Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system：A Korean gynecologic-oncology group study[J].Int J Gynecol Cancer，2016，26（4）：711-715.
[20]
RCOG/BSGE.Management of endometrial hyperplasia[J].Green-top Guideline NO.67.RCOG/BSGE Joint Guideline，2016，67：1-31.
[21]
Turok DK，Eisenberg DL，Teal SB，et al.A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement[J].Am J Obstet Gynecol，2016，215（5）：599.e1-599.e6.
[22]
Sletten ET，Arnes M，Vereide AB，et al.Intrauterine progestin therapy as a new approach to premalignant endometrial polyps：A prospective observational study[J].Anticancer Res，2019，39（9）：4897-4903.
[23]
Roberts H，Hickey M.Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen：A cochrane review summary[J].Maturitas，2016，89：1-2.
[24]
Chen X.The current situation of the levonorgestrel intrauterine system（LNG-IUS）in conservative treatment for patients with early-stage endometrial cancer and atypical hyperplasia[J].J Gynecol Oncol，2019，30（4）：e79.
[25]
Leone Roberti Maggiore U，Martinelli F，Dondi G，et al.Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer：a retrospective study[J].J Gynecol Oncol，2019，30（4）：e57.
京公网安备 11010502046607号